We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Dr
Mark
Travis
mark.travis-2@manchester.ac.uk
Dr
Mark
Travis
mark.travis-2@manchester.ac.uk
Noninfective enteritis and colitis
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Our immune system is crucial in keeping us healthy by protecting us from infection. However, the immune system must be carefully controlled so that it only attacks harmful pathogens, and not the organs and tissues of our own body.
If the immune system starts to attack our own body, so-called
autoimmune diseases can occur. A highly prevalent autoimmune disease in Western societies is inflammatory bowel disease (IBD), and affects hundreds of thousands of people in the UK. IBD occurs when the body’s immune system attacks our gut, often resulting in severe pain and weight loss. Despite the devastating effects of IBD, current treatments are poor and little is known about the underlying
causes of IBD. Thus, gaining a better understanding how IBD develops will provide important potential new targets to treat the conditions.
Our study, arising from a recently awarded Medical Research Council-funded project grant, aims to discover important molecular and cellular pathways that contribute to the development and symptoms of IBD. Specifically, we will identify focus on identifying genes, cells and molecules that are altered in IBD patients versus healthy individuals, with a focus on cells of the adaptive immune system (T-cells, regulatory T-cells, dendritic cells). To achieve these aims, we will obtain intestinal samples from patients undergoing scheduled endoscopy or surgery and compare 'healthy' tissue to inflamed tissue from IBD patients. Our work will therefore aim to uncover important biological differences that contribute to IBD, therefore identifying potential therapeutic targets for this devastating disease.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Clinical Laboratory Study;
You can take part if:
You may not be able to take part if:
- Language barriers (if no interpreter available) - Vulnerable groups (Learning Difficulties, Impaired consciousness, etc) - For laboratory health and safety reasons, any patients who have been diagnosed with HIV or hepatitis will be excluded from the study.
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
The study is sponsored by University of Manchester and funded by KENNETH RAININ FOUNDATION; Medical Research Council (MRC); .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 18282
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
